Nancy A. Grygiel - May 2, 2022 Form 4 Insider Report for AMGEN INC (AMGN)

Role
SVP & CCO
Signature
/s/ Nancy A. Grygiel
Stock symbol
AMGN
Transactions as of
May 2, 2022
Transactions value $
-$13,162
Form type
4
Date filed
5/4/2022, 07:57 PM
Previous filing
Apr 29, 2022
Next filing
May 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Award $0 +649 +4.53% $0.00 15K May 2, 2022 Direct F1
transaction AMGN Common Stock Tax liability -$13.2K -57 -0.38% $230.92 14.9K May 2, 2022 Direct F2, F3
holding AMGN Common Stock 93 May 2, 2022 401(k) Plan F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Award $0 +5.3K $0.00 5.3K May 2, 2022 Common Stock 5.3K $230.92 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.
F2 These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which vest in one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3 These shares include 523 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
F5 These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.